Metformin and Galantamine Combination Modestly Improves Sarcopenia Symptoms
Research in the field of sarcopenia, the age-related loss of muscle mass and strength, is often focused on developing small molecule therapies that don’t offer significant improvement over traditional methods like resistance exercise. However, a recent breakthrough in functional outcomes from a clinical trial of RJx-01, a combination of metformin and galantamine, by Rejuvenate Biomed has shown promising results in treating sarcopenia. Participants treated with RJx-01 experienced improved muscle strength recovery, leg acceleration, and reduced neuromuscular fatigue, indicating the potential of this therapy in addressing the unmet need for effective sarcopenia treatments. This innovative approach highlights the importance of exploring new therapies in aging research to improve health outcomes.
The Phase 1b trial results from Rejuvenate Biomed’s proprietary combination, RJx-01, demonstrate its potential in enhancing muscle strength and functional movement in individuals with sarcopenia. By combining metformin and galantamine, RJx-01 offers a novel approach to addressing the challenges of muscle aging and disuse-induced sarcopenia. The positive outcomes observed in the trial suggest that RJx-01 could be a valuable addition to the treatment options available for this condition, providing hope for those suffering from muscle loss and weakness due to aging.
Link: https://www.rejuvenatebiomed.com/en/news/clinical-trial-demonstrates-the-therapeutic-potential-of-rjx-01-in-sarcopenia
